Fig. 6

β-escin downregulates full-length HER2, ICD-HER2, ALDH1 and CD44 as well as vimentin in JIMT-1 xenograft tumors. A, B β-escin administration resulted in a marked downregulation of full-length HER2 and ICD-HER2 in JIMT-1 xenograft tumors. Tumor tissues were immunostained for full-length HER2 (polyclonal antibody 29D8, green) and ICD-HER2 (monoclonal antibody 4B5, green) with DAPI (blue). High magnification images were taken using confocal microscopy (original magnification: ×500). Quantitative graphs of signal intensities for full-length HER2 (A, ****p<0.0001) and ICD-HER2 (B, ****p<0.0001) are shown in the right panel, respectively. C, D Immunohistochemical analysis for the ALDH1 (C, red) and CD44 (D, red) in JIMT-1 xenograft tumors. Signal intensities were quantified and the graphs are shown in the right panels (****p<0.0001). E Influence of β-escin on vimentin expression in vivo. The immunofluorescence images of vimentin (green) with DAPI (blue) are shown at high magnification (×500), and the vimentin intensity was quantified (****p<0.0001). Images were taken under a confocal microscope and the fluorescence intensity was analyzed with a histogram tool within the Zen blue software. Data were analyzed using unpaired Student’s t-test